Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company
Cellectis to advance two lead in vivo programs .HEAL-101 and .HEAL-201 in severe dyslipidemias with preliminary Phase 1 data planned in H2 2027 and H1 2028, respectively Transformation supported by continuing existing cell therapy partnerships while …